Federal Register Notice: FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will meet 1/12-13/10 from 8 a.m. to 5 p.m. at the Hilton Washington DC/Silver Spring, The Ballrooms, 8727 Colesville Rd., Silver Spring, MD. On 1/12, the committee will discuss an Actelion Pharmaceuticals NDA, Zavesca (miglustat), 100 mg capsules for treating progressive neurological manifestations in patients with Niemann-Pick Disease (type C). On 1/13, the committee will discuss an NDA from Orphan Europe SARL for Carbglu (carglumic acid), 200 mg tablets for treating hyperammonemia in patients with N acetyl glutamate synthetase (NAGS) deficiency, an inherited disorder that causes ammonia to accumulate in the blood. Contact Paul Tran, (301) 827-7001. To view this notice, click here.